Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | LGMN | Q99538 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15202815 | 1.00 | MAPK1 (0.41) | MAPK1ALOX15TSHRP2RX7MAPT | |
| SCHEMBL2526358 | 1.00 | MAPK1 (0.41) | MAPK1ALOX15TSHRP2RX7MAPT | |
| SCHEMBL19657662 | 0.90 | P2RX7 (0.38) | MAPK1ALOX15TSHRP2RX7 | |
| SCHEMBL19148721 | 0.89 | P2RX7 (0.39) | MAPK1ALOX15TSHRP2RX7 | |
| SCHEMBL16884665 | 0.88 | P2RX7 (0.37) | MAPK1ALOX15TSHRP2RX7 | |
| SCHEMBL15166810 | 0.87 | MAPK1 (0.36) | MAPK1ALOX15TSHRP2RX7MAPT | |
| SCHEMBL18810031 | 0.86 | P2RX7 (0.38) | MAPK1ALOX15TSHRP2RX7 | |
| SCHEMBL16104432 | 0.86 | P2RX7 (0.35) | MAPK1TSHRP2RX7 | |
| SCHEMBL1289681 | 0.85 | P2RX7 (0.43) | MAPK1TSHRP2RX7MAPTALDH1A1 | |
| SCHEMBL15181617 | 0.83 | TSHR (0.39) | TSHRNPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 522 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745129-A2 | COMPOUND HAVING CYCLIC STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2026-05-20 | — | — | EP | disclosed |
| EP-4741386-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-12624044-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4735422-A1 | SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF TREATING PHENYLKETONURIA AND OTHER AMINO ACIDURIAS | Sanofi (FR) | 2026-05-06 | — | — | EP | disclosed |
| US-12612408-B2 | Pyrazolone-fused pyrimidine compound, preparation method for same and applications thereof | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2026-04-28 | — | — | US | disclosed |
| US-12606533-B2 | 3-phenylpropylamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-04-21 | — | — | US | disclosed |
| US-12606568-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4719385-A2 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINES AS ANTI-INFECTIOUS AGENTS | University of Vermont and State Agricultural College (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-3682881-B1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO CO LTD (JP) | 2026-04-01 | — | — | EP | disclosed |
| EP-4168399-B1 | COMPOUNDS AND THEIR USES AS MIF INHIBITORS | NANJING IMMUNOPHAGE BIOMEDICAL CO LTD (CN) | 2026-04-01 | — | — | EP | disclosed |
| US-20100184813-A1 | CHEMICAL COMPOUNDS 553 | ASTRAZENECA AB (SE) | 2010-07-22 | — | — | US | disclosed |
| US-20100184813-A1 | CHEMICAL COMPOUNDS 553 | ASTRAZENECA AB (SE) | 2010-07-22 | — | — | US | disclosed |
| WO-2010070343-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AND THEIR USES TO TREAT DIABETES | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010070343-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AND THEIR USES TO TREAT DIABETES | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | WO | disclosed |
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | PROSIDION LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | PROSIDION LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | PROSIDION LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| EP-2120911-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | Prosidion Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008099221-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | PROSIDION LIMITED (GB) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008099221-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | PROSIDION LIMITED (GB) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624044-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCC1, SMARCA2 | MAPK1 2170/4885ALOX15 4768/4885TSHR 2477/4885 |
| US-12606533-B2 | 3-phenylpropylamine derivative | SF3A1, SF1, HTR1D | MAPK1 1850/4885ALOX15 1326/4885TSHR 1117/4885 |
| US-12606568-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCD1, SMARCC1 | MAPK1 1413/4885ALOX15 4743/4885TSHR 2649/4885 |
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | CPS1, GOT2, GPR119 | MAPK1 2531/4885ALOX15 2067/4885TSHR 1086/4885 |
| US-20100184813-A1 | CHEMICAL COMPOUNDS 553 | GCGR, DGAT1, GPBAR1 | MAPK1 2172/4885ALOX15 3018/4885TSHR 445/4885 |
| US-12612408-B2 | Pyrazolone-fused pyrimidine compound, preparation method for same and applications thereof | WEE1, WEE2, TK1 | MAPK1 64/4885ALOX15 2533/4885TSHR 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.